Myokines in insulin resistance and type 2 diabetes

Diabetologia

Volumn 57, Issue 6, 2014, Pages 1087-1099

  Eckardt, Kristin ^a   Görgens, Sven W ^a   Raschke, Silja ^a   Eckel, Jürgen ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Exercise; Inflammation; Insulin resistance; Metabolism; Myokines; Review; Skeletal muscle; Therapeutical targets; Type 2 diabetes

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR 21; FOLLISTATIN; FOLLISTATIN LIKE 1; GLUCOSE; INSULIN; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 6; IRISIN; MYOKINE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CYTOKINE RELEASE; DISEASE ASSOCIATION; EXERCISE; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; METABOLIC REGULATION; METABOLISM; MUSCLE CONTRACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SEDENTARY LIFESTYLE; SKELETAL MUSCLE; IMMUNOLOGY; PHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; EXERCISE; HUMANS; INSULIN RESISTANCE; MUSCLE, SKELETAL;

EID: 84901237824     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3224-x     Document Type: Review

References (139)

1. Febbraio MA, Pedersen BK (2005) Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev 33:114-119
2. Raschke S, Eckardt K, Holven KB, Jensen J, Eckel J (2013) Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS One 8:e62008
3. Hartwig S, Raschke S, Knebel B et al (2013) Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta. doi: 10.1016/j.bbr.2011.03.031
4. Norheim F, Raastad T, Thiede B, Rustan AC, Drevon CA, Haugen F (2011) Proteomic identification of secreted proteins from human skeletal muscle cells and expression in response to strength training. Am J Physiol Endocrinol Metab 301:E1013-E1021
5. Raschke S, Eckel J (2013) Adipo-myokines: two sides of the same coin - mediators of inflammation and mediators of exercise. Mediat Inflamm 2013:320724
6. Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457-465
7. Thyfault JP, Booth FW (2011) Lack of regular physical exercise or too much inactivity. Curr Opin Clin Nutr Metab Care 14:374-378
8. Bergouignan A, Rudwill F, Simon C, Blanc S (2011) Physical inactivity as the culprit of metabolic inflexibility: evidences from bed-rest studies. J Appl Physiol 11:1201-1210
9. Alibegovic AC, Sonne MP, Hojbjerre L et al (2010) Insulin resistance induced by physical inactivity is associated with multiple transcriptional changes in skeletal muscle in young men. Am J Physiol Endocrinol Metab 299:E752-E763
10. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund PB (2000) Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529:237-242
11. Steensberg A, Febbraio MA, Osada T et al (2001) Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537:633-639
12. Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA (2004) Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 18:992-994
13. Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379-1406
14. Whitham M, Chan MH, Pal M et al (2012) Contraction-induced interleukin-6 gene transcription in skeletal muscle is regulated by c-Jun terminal kinase/activator protein-1. J Biol Chem 287:10771-10779
15. Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Lorenzo M (2008) Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57:3211-3221
16. Holmes AG, Mesa JL, Neill BA et al (2008) Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARα and UCP2 expression in rats. J Endocrinol 198:367-374
17. Sadagurski M, Norquay L, Farhang J, D'Aquino K, Copps K, White MF (2010) Human IL6 enhances leptin action in mice. Diabetologia 53:525-535
18. Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364-3375
19. Carey AL, Steinberg GR, Macaulay SL et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688-2697
20. Jiang LQ, Duque-Guimaraes DE, Machado UF, Zierath JR, Krook A (2012) Altered response of skeletal muscle to IL-6 in type 2 diabetic patients. Diabetes 62:355-361
21. Febbraio MA, Steensberg A, Keller C et al (2003) Glucose ingestion attenuates interleukin-6 release from contracting skeletal muscle in humans. J Physiol 549:607-612
22. Keller C, Steensberg A, Pilegaard H et al (2001) Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J 15:2748-2750
23. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643-1648
24. Steensberg A, Fischer CP, Sacchetti M et al (2003) Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631-638
25. Fritsche L, Hoene M, Lehmann R et al (2010) IL-6 deficiency in mice neither impairs induction of metabolic genes in the liver nor affects blood glucose levels during fasting and moderately intense exercise. Diabetologia 53:1732-1742
26. Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060-1067
27. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784-2789
28. Jiang LQ, Franck N, Egan B et al (2013) Autocrine role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7. Am J Physiol Endocrinol Metab 305:E1359-E1366
29. Stanya KJ, Jacobi D, Liu S et al (2013) Direct control of hepatic glucose production by interleukin-13 in mice. J Clin Invest 123:261-271
30. van Hall G, Steensberg A, Sacchetti M et al (2003) Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005-3010
31. Wolsk E, Mygind H, Grondahl TS, Pedersen BK, van Hall G (2010) IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am J Physiol Endocrinol Metab 299:E832-E840
32. Petersen EW, Carey AL, Sacchetti M et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155-E162
33. Kelly M, Gauthier MS, Saha AK, Ruderman NB (2009) Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 58:1953-1960
34. Macdonald TL, Wan Z, Frendo-Cumbo S, Dyck DJ, Wright DC (2013) IL-6 and epinephrine have divergent fiber type effects on intramuscular lipolysis. J Appl Physiol (1985) 115:1457-1463
35. Peterson JM, Pizza FX (2009) Cytokines derived from cultured skeletal muscle cells after mechanical strain promote neutrophil chemotaxis in vitro. J Appl Physiol 106:130-137
36. Nieman DC, Davis JM, Brown VA et al (2004) Influence of carbohydrate ingestion on immune changes after 2 h of intensive resistance training. J Appl Physiol 96:1292-1298
37. Nielsen AR, Mounier R, Plomgaard P et al (2007) Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre type composition. J Physiol 584:305-312
38. Tamura Y, Watanabe K, Kantani T, Hayashi J, Ishida N, Kaneki M (2011) Upregulation of circulating IL-15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the beneficial effects of endurance exercise? Endocr J 58:211-215
39. Yeo NH, Woo J, Shin KO, Park JY, Kang S (2012) The effects of different exercise intensity on myokine and angiogenesis factors. J Sports Med Phys Fitness 52:448-454
40. Riechman SE, Balasekaran G, Roth SM, Ferrell RE (2004) Association of interleukin-15 protein and interleukin-15 receptor genetic variation with resistance exercise training responses. J Appl Physiol 97:2214-2219
41. Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Al-Abri S, Al-Lawati J, Al-Maskari M (2013) Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol 2013:976810
42. Barra NG, Reid S, MacKenzie R et al (2010) Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity (Silver Spring) 18:1601-1607
43. 14C]-triolein load. Biochim Biophys Acta 1761:37-42
44. Quinn LS, Strait-Bodey L, Anderson BG, Argiles JM, Havel PJ (2005) Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol Int 29:449-457
45. Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM, Argiles JM (2009) Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab 296:E191-E202
46. Matthews VB, Astrom MB, Chan MH et al (2009) Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase. Diabetologia 52:1409-1418
47. Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50:431-438
48. Rasmussen P, Brassard P, Adser H et al (2009) Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 94:1062-1069
49. Tsuchida A, Nakagawa T, Itakura Y et al (2001) The effects of brain-derived neurotrophic factor on insulin signal transduction in the liver of diabetic mice. Diabetologia 44:555-566
50. Bouzakri K, Plomgaard P, Berney T, Donath MY, Pedersen BK, Halban PA (2011) Bimodal effect on pancreatic beta-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 60:1111-1121
51. Ellingsgaard H, Ehses JA, Hammar EB et al (2008) Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 105:13163-13168
52. Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481-1489
53. Ueda SY, Yoshikawa T, Katsura Y, Usui T, Nakao H, Fujimoto S (2009) Changes in gut hormone levels and negative energy balance during aerobic exercise in obese young males. J Endocrinol 201:151-159
54. Martins C, Robertson MD, Morgan LM (2008) Effects of exercise and restrained eating behaviour on appetite control. Proc Nutr Soc 67:28-41
55. Shirazi R, Palsdottir V, Collander J et al (2013) Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci U S A 110:16199-16204
56. Henningsen J, Rigbolt KT, Blagoev B, Pedersen BK, Kratchmarova I (2010) Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics 9:2482-2496
57. Shah R, Hinkle CC, Ferguson JF et al (2011) Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 60:1512-1518
58. Plomgaard P, Hansen J, Bianda V, Pedersen BK, Bouzakri K (2013) Fractalkine is a novel myokine which protects myotubes from TNF-alpha induced insulin resistance. Diabetologia 56(Suppl 1):S79 (Abstract 178)
59. Lee YS, Morinaga H, Kim JJ et al (2013) The fractalkine/CX3CR1 system regulates beta cell function and insulin secretion. Cell 153:413-425
60. Sell H, Habich C, Eckel J (2012) Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 8:709-716
61. Gleeson M (2007) Immune function in sport and exercise. J Appl Physiol 103:693-699
62. Pedersen BK, Saltin B (2006) Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports 16(Suppl 1):3-63
63. Donges CE, Duffield R, Drinkwater EJ (2010) Effects of resistance or aerobic exercise training on interleukin-6, C-reactive protein, and body composition. Med Sci Sports Exerc 42:304-313
64. Christiansen T, Paulsen SK, Bruun JM, Pedersen SB, Richelsen B (2010) Exercise training versus diet-induced weight-loss on metabolic risk factors and inflammatory markers in obese subjects: a 12-week randomized intervention study. Am J Physiol Endocrinol Metab 298:E824-E831
65. Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK (2007) Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports 17:580-587
66. Drummond MJ, Timmerman KL, Markofski MM et al (2013) Short-term bed rest increases TLR4 and IL-6 expression in skeletal muscle of older adults. Am J Physiol Regul Integr Comp Physiol 305:R216-R223
67. King DE, Carek P, Mainous AG III, Pearson WS (2003) Inflammatory markers and exercise: differences related to exercise type. Med Sci Sports Exerc 35:575-581
68. Abramson JL, Vaccarino V (2002) Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 162:1286-1292
69. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP (2001) Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 153:242-250
70. Mattusch F, Dufaux B, Heine O, Mertens I, Rost R (2000) Reduction of the plasma concentration of C-reactive protein following nine months of endurance training. Int J Sports Med 21:21-24
71. de Lemos ET, Oliveira J, Pinheiro JP, Reis F (2012) Regular physical exercise as a strategy to improve antioxidant and anti-inflammatory status: benefits in type 2 diabetes mellitus. Oxidative Med Cell Longev 2012:741545
72. Stewart LK, Flynn MG, Campbell WW et al (2007) The influence of exercise training on inflammatory cytokines and C-reactive protein. Med Sci Sports Exerc 39:1714-1719
73. Francaux M (2009) Toll-like receptor signalling induced by endurance exercise. Appl Physiol Nutr Metab 34:454-458
74. Lambert CP, Wright NR, Finck BN, Villareal DT (2008) Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol (1985) 105:473-478
75. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA (2011) The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11:607-615
76. Liang H, Hussey SE, Sanchez-Avila A, Tantiwong P, Musi N (2013) Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One 8:e63983
77. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-α production in humans. FASEB J 17:884-886
78. Lambernd S, Taube A, Schober A et al (2012) Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways. Diabetologia 55:1128-1139
79. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP (2007) Role of myokines in exercise and metabolism. J Appl Physiol 103:1093-1098
80. Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4-7
81. Duncan BB, Schmidt MI, Pankow JS et al (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799-1805
82. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-E751
83. 2+/calcineurin-NFAT-mediated signaling. Mol Cells 18:1-9
84. Banzet S, Koulmann N, Sanchez H et al (2007) Contraction-induced interleukin-6 transcription in rat slow-type muscle is partly dependent on calcineurin activation. J Cell Physiol 210:596-601
85. Chan MH, McGee SL, Watt MJ, Hargreaves M, Febbraio MA (2004) Altering dietary nutrient intake that reduces glycogen content leads to phosphorylation of nuclear p38 MAP kinase in human skeletal muscle: association with IL-6 gene transcription during contraction. FASEB J 18:1785-1787
86. Petersen AM, Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol 98:1154-1162
87. Dinarello CA (2000) The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343:732-734
88. Görgens SW, Eckardt K, Elsen M, Tennagels N, Eckel J (2014) Chitinase-3-like protein 1 protects skeletal muscle from TNFα-induced inflammation and insulin resistance. Biochem J. doi: 10.1042/BJ20131151
89. Nielsen AR, Erikstrup C, Johansen JS et al (2008) Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 57:3078-3082
90. Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK (1999) Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 515:287-291
91. Bernecker C, Scherr J, Schinner S, Braun S, Scherbaum WA, Halle M (2013) Evidence for an exercise induced increase of TNF-α and IL-6 in marathon runners. Scand J Med Sci Sports 23:207-214
92. Paulsen G, Mikkelsen UR, Raastad T, Peake JM (2012) Leucocytes, cytokines and satellite cells: what role do they play in muscle damage and regeneration following eccentric exercise? Exerc Immunol Rev 18:42-97
93. Sigal RJ, Kenny GP, Boule NG et al (2007) Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 147:357-369
94. Cypess AM, Lehman S, Williams G et al (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360:1509-1517
95. 18F-FDG-detected BAT in humans. J Clin Endocrinol Metab 96:192-199
96. Zingaretti MC, Crosta F, Vitali A et al (2009) The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J 23:3113-3120
97. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM et al (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360:1500-1508
98. Bostrom P, Wu J, Jedrychowski MP et al (2012) A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463-468
99. Camporez JP, Jornayvaz FR, Petersen MC et al (2013) Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154:3099-3109
100. Raschke S, Elsen M, Gassenhuber H et al (2013) Evidence against a beneficial effect of irisin in humans. PLoS One 8:e73680
101. Erickson HP (2013) Irisin and FNDC5 in retrospect: an exercise hormone or a transmembrane receptor? Adipocyte 2:289-293
102. Timmons JA, Baar K, Davidsen PK, Atherton PJ (2012) Is irisin a human exercise gene? Nature 488:E9-E10
103. Pekkala S, Wiklund P, Hulmi JJ et al (2013) Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health? J Physiol 591:5393-5400
104. Norheim F, Langleite TM, Hjorth M et al (2014) The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J 281:739-749
105. Huh JY, Panagiotou G, Mougios V et al (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:1725-1738
106. Kraemer RR, Shockett P, Webb ND, Shah U, Castracane VD (2014) A transient elevated irisin blood concentration in response to prolonged, moderate aerobic exercise in young men and women. Horm Metab Res 46:150-154
107. Gouni-Berthold I, Berthold HK, Huh JY et al (2013) Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS ONE 8:e72858
108. Moreno-Navarrete JM, Ortega F, Serrano M et al (2013) Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98:E769-E778
109. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity - correlation with body mass index. Peptides 39:125-130
110. Choi YK, Kim MK, Bae KH et al (2013) Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 100:96-101
111. Zhang Y, Li R, Meng Y et al (2013) Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 63:514-525
112. Lee D, Zhou Y, Tu M et al (2013) Irisin does not induce browning of mouse or human adipocytes. Diabetes 62(Suppl 1):A25 (Abstract)
113. Cheng X, Zhu B, Jiang F, Fan H (2011) Serum FGF-21 levels in type 2 diabetic patients. Endocr Res 36:142-148
114. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A, Walsh K (2008) FGF21 is an Akt-regulated myokine. FEBS Lett 582:3805-3810
115. Hojman P, Pedersen M, Nielsen AR et al (2009) Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 58:2797-2801
116. Yang SJ, Hong HC, Choi HY et al (2011) Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf) 75:464-469
117. Besse-Patin A, Montastier E, Vinel C et al (2013) Effect of endurance training on skeletal muscle myokine expression in obese men: identification of apelin as a novel myokine. Int J Obes (Lond). doi: 10.1038/ijo.2013.158
118. Cuevas-Ramos D, Almeda-Valdes P, Meza-Arana CE et al (2012) Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One 7:e38022
119. Kim KH, Kim SH, Min YK, Yang HM, Lee JB, Lee MS (2013) Acute exercise induces FGF21 expression in mice and in healthy humans. PLoS One 8:e63517
120. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426-437
121. Inagaki T, Dutchak P, Zhao G et al (2007) Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425
122. Cuevas-Ramos D, Aguilar-Salinas CA, Gomez-Perez FJ (2012) Metabolic actions of fibroblast growth factor 21. Curr Opin Pediatr 24:523-529
123. Coskun T, Bina HA, Schneider MA et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018-6027
124. Kharitonenkov A, Shiyanova TL, Koester A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627-1635
125. Kharitonenkov A, Wroblewski VJ, Koester A et al (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774-781
126. Xu J, Lloyd DJ, Hale C et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-259
127. Holland WL, Adams AC, Brozinick JT et al (2013) An FGF21-adiponectin- ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 17:790-797
128. Lin Z, Tian H, Lam KS et al (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17:779-789
129. Gaich G, Chien JY, Fu H et al (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333-340
130. Ouchi N, Oshima Y, Ohashi K et al (2008) Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem 283:32802-32811
131. Gorgens SW, Raschke S, Holven KB, Jensen J, Eckardt K, Eckel J (2013) Regulation of follistatin-like protein 1 expression and secretion in primary human skeletal muscle cells. Arch Physiol Biochem 119:75-80
132. Lehr S, Hartwig S, Lamers D et al (2012) Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics 11:M111.010504
133. Shimano M, Ouchi N, Nakamura K et al (2011) Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proc Natl Acad Sci U S A 108:E899-E906
134. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K (2008) Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 117:3099-3108
135. Ogura Y, Ouchi N, Ohashi K et al (2012) Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models. Circulation 126:1728-1738
136. Mashili FL, Austin RL, Deshmukh AS et al (2011) Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev 27:286-297
137. Potthoff MJ, Inagaki T, Satapati S et al (2009) FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A 106:10853-10858
138. Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203-206
139. Adams DC, Karolak MJ, Larman BW, Liaw L, Nolin JD, Oxburgh L (2010) Follistatin-like 1 regulates renal IL-1β expression in cisplatin nephrotoxicity. Am J Physiol Ren Physiol 299:F1320-F1327